Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ayvakit
Pharma
Blueprint boosts Ayvakit peak sales estimate to $2B
Blueprint expects Ayvakit's 2024 revenue to come between $360 million and $390 million, which at the midpoint marks 84% year-over-year growth.
Angus Liu
Feb 15, 2024 7:00am
Blueprint's Ayvakit picks up long-awaited label expansion
May 22, 2023 4:28pm
Blueprint lays out $1.5B expansion plan for Ayvakit
Feb 17, 2023 10:53am
'Commercial debate' looms over Blueprint's Ayvakit expansion
Aug 17, 2022 11:06am
Blueprint exec spots key Ayvakit expansion, dealmaking plan
Aug 11, 2022 11:34am
Blueprint assembles $1.25B for cancer portfolio expansion
Jun 30, 2022 4:29pm